Randomized phase III study comparing carboplatin plus pemetrexed followed by pemetrexed versus docetaxel in elderly patients with advanced non-squamous non-small-cell lung cancer (JCOG1210/WJOG7813L).
Isamu Okamoto(Kyushu University Hospital), Kazuhiko Nakagawa(Osaka Red Cross Hospital), Haruyasu Murakami(Shizuoka Cancer Center), Nobuyuki Yamamoto(Wakayama Medical University), Koichi Azuma(Kyushu University Hospital), Atsushi Horiike(The Cancer Institute Hospital), H. Daga(Osaka City General Hospital), Kiyotaka Yoh(National Cancer Center Hospital East), Yukio Hosomi(Tokyo Metropolitan Komagome Hospital), Tomohiro Ozaki(Kishiwada City Hospital), Shinji Atagi(National Institute of Technology, Nara College), Shogo Nomura(Juntendo University), Hidehito Horinouchi(Tokyo National Hospital), Masahiko Ando(Nagoya University Hospital), Shunichi Sugawara(Sendai Kousei Hospital), Yuichiro Ohe(National Cancer Center), Yuka Fujita, Yasuto Yoneshima(Kyushu University), Hiroaki Okamoto(Yokohama Municipal Citizen's Hospital), Hiroshi Nokihara(Tokushima University Hospital)
Cited by 8
Related Papers
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
|New England Journal of Medicine|2009|8.2k
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer
|New England Journal of Medicine|2014|3.2k